Regeneron Pharmaceuticals Inc vs Teucrium Soybean Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Teucrium Soybean Fund trades at $27.66. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | SOYB | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $852.03 | $27.84 |
52-Week Low | $555.51 | $21.46 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SOYB trades at $27.84, up 0.69% today, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong momentum indicators, with RSI levels indicating overbought conditions. Recent news highlights commodity price trends influencing agricultural stocks.
The outlook remains tied to commodity market dynamics, with potential upside from rising soybean prices but risks from geopolitical tensions and volatility. Investors should weigh technical overbought signals against fundamental growth catalysts in the agricultural sector.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →